Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus

Diseases of the Esophagus

Volumn 21, Issue 2, 2008, Pages 151-158

  Smithers, B M ^a   Couper, G C ^a   Thomas, J M ^a   Wong, D ^b   Gotley, D C ^a   Martin, I ^a   Harvey, J A ^a   Thomson, D B ^a   Walpole, E T ^a   Watts, N ^b   Burmeister, B H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Wesley Private Hospital   (Australia)

Author keywords

Esophageal adenocarcinoma; Neoadjuvant therapy; Positron emission tomography; Tumor response

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADJUVANT THERAPY; ARTICLE; CALCULATION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG UPTAKE; ESOPHAGEAL ADENOCARCINOMA; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; TUMOR REGRESSION;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 39049099397     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00732.x     Document Type: Article

References (39)

1. Blot W J, Devesa S S, Fraumeni J F Jr. Continuing climb in rates of esophageal adenocarcinoma: An update. JAMA 1993; 270: 1320.
2. Reis L A G, Eisner M P, Kosary C L et al. (eds). SEER Cancer Statistics Review, 1973-97. Bethesda, MD: National Cancer Institute, 2000.
3. Berrino F, Capocaccia R, Estève J et al. (eds). Survival of Cancer Patients in Europe: The EUROCARE-2 Study. IARC Scientific Publications No. 151, Lyon: IARC, 1999.
4. Lund O, Hasenkam J M, Aagaard M T, Kimose H H. Time-related changes in characteristics of prognostic significance in carcinomas of the oesophagus and cardia. Br J Surg 1989; 76: 1303-7.
5. Earlam R, Cunha-Melo J R. Oesophageal squamous cell carcinoma: II. A critical review of surgery. Br J Surg 1980; 67: 381-90.
6. Muller J M, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77: 845-57.
7. Donington J S, Miller D L, Allen M S et al. Tumor response to induction chemoradiation: Influence on survival after esophagectomy. Eur J Cardiothorac Surg 2003; 24: 631-7.
8. Ancona E, Ruol A, Santi S et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma. Cancer 2001; 91: 2165-74.
9. Law S, Fok M, Chow S, Chu K M, Wong J I. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial. J Thoracic Cardiovascular Surg 1997; 114: 210-7.
10. Roth J A, Pass H I, Flanagan M M, Graeber G M, Rosenberg J C, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine and bleomycin for carcinoma of the esophagus. J Thoracic Cardiovascular Surg 1988; 96: 242-8.
11. Schlag P. Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus. Arch Surg 1992; 127: 1446-50.
12. (MRC OEO2) Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: A randomised controlled trial. Lancet 2002; 359: 1727-33.
13. Gebski V, Burmeister B, Smithers B M, Foo K, Zulcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007; 8: 226-34.
14. Westerterp M, van Westreenen H, Reitsma J et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy - systemic review. Radiology 2005; 236: 841-51.
15. McAteer D, Wallis F, Couper G W et al. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal cancer. Br J Radiol 1999; 72: 525-9.
16. Flanagan F L, Dehdashti F, Siegel B A et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997; 168: 417-24.
17. Cook G, Taylor H, Mason R, Rankin S, Fogelman I. A comparison of 18FDG PET and CT in the staging of oesophageal carcinoma. J Nuclear Med 1997; 38(Suppl): 247. Abstract 1043.
18. Block M I, Patterson G A, Sundaresan R S et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thoracic Surg 1997; 64: 776-7.
19. Luketich J D, Friedman D M, Weigel T L et al. Evaluation of distant metastases in oesophageal cancer: 100 consecutive positron emission tomography scans. Ann Thoracic Surg 1999; 68: 1133-6.
20. Flamen P, Lerut A, Van Cutsem E. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-10.
21. Kneist W, Schreckenberger M, Bartenstein P, Menzel C, Oberholzer K, Junginger T. prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg 2004; 139: 1043-9.
22. Couper G W, McAteer D, Wallis F et al. The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998; 85: 1403-6.
23. Brucher B, Weber W, Bauer M et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 2001; 233: 300-9.
24. Weber W A, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.
25. Kato H, Kuwano H, Nakajima M. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184: 279-83.
26. Flamen P, Van Cutsem E, Lerut A et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Onc 2002; 13: 361-8.
27. Downey R J, Akhurst T, Ilson D et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: Results of a prospective trial. J Clin Oncol 2003; 21: 428-32.
28. Song S, Kim J H, Ryu J S et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiation Oncol Biol Phys 2005; 63: 1053-9.
29. Swisher S, Maish M, Eramus J et al. Utility of PET, CT and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78: 1152-60.
30. Brink I, Hentschel M, Bley T et al. Effects of neoadjuvant radio-chemotherapy on 18F-FDG-Pet in esophageal carcinoma. EJSO 2004; 30: 544-50.
31. Levine E, Farmer M, Clark P et al. Predictive value of 18-fluro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006; 243: 472-8.
32. Boellaard R, Krak N C, Hoekstra O et al. Effects of noise, image resolution and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004; 45: 1519-27.
33. Mandard A M, Dalibard F, Mandard J C et al. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathological correlations. Cancer 1994; 73: 2580-686.
34. Burmeister B H, Smithers B M, Gebski V et al. A randomised phase III study comparing surgery alone with chemoradiation therapy followed by surgery for resectable carcinoma of the oesophagus: An intergroup study of the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Lancet Oncol 2005; 6: 659-68.
35. Walsh T, Noonan N, Hollywood D, Kelly A et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
36. Urba S, Orringer M, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with local-regional esophageal carcinoma. J Clin Oncol 2001; 19: 305-13.
37. Cerfolio R, Bryant A, Ohja B et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemotherapy. J Thorac Cardiovasc Surg 2005; 129: 1232-41.
38. Forastiere A A, Orringer M B, Perez-Tamayo C et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: Final report. J Clin Oncol 1993; 11: 1118-23.
39. Wieder H A, Brucher B, Zimmermann F et al. Time course of tumour metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-8.